Partner-delivered HIV self-test kits with and without financial incentives in antenatal care and index patients with HIV in Malawi: a three-arm, cluster-randomised controlled trial.


Journal

The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665

Informations de publication

Date de publication:
07 2021
Historique:
received: 30 08 2020
revised: 15 03 2021
accepted: 22 03 2021
entrez: 18 6 2021
pubmed: 19 6 2021
medline: 24 6 2021
Statut: ppublish

Résumé

Secondary distribution of HIV self-testing (HIVST) kits by patients attending clinic services to their partners could improve the rate of HIV diagnosis. We aimed to investigate whether secondary administration of HIVST kits, with or without an additional financial incentive, via women receiving antenatal care (ANC) or via people newly diagnosed with HIV (ie, index patients) could improve the proportion of male partners tested or the number of people newly diagnosed with HIV. We did a three-arm, open-label, pragmatic, cluster-randomised trial of 27 health centres (clusters), eligible if they were a government primary health centre providing ANC, HIV testing, and ART services, across four districts of Malawi. We recruited women (aged ≥18 years) attending their first ANC visit and whose male partner was available, not already taking ART, and not already tested for HIV during this pregnancy (ANC cohort), and people (aged ≥18 years) with newly diagnosed HIV during routine clinic HIV testing who had at least one sexual contact not already known to be HIV-positive (index cohort). Centres were randomly assigned (1:1:1), using a public selection of computer-generated random allocations, to enhanced standard of care (including an invitation for partners to attend HIV testing services), HIVST only, or HIVST plus a US$10 financial incentive for retesting. The primary outcome for the ANC cohort was the proportion of male partners reportedly tested, as ascertained by interview with women in this cohort at day 28. The primary outcome for the index cohort was the geometric mean number of new HIV-positive people identified per facility within 28 days of enrolment, as measured by observed HIV test results. Cluster-level summaries compared intervention with standard of care by intention to treat. This trial is registered with ClinicalTrials.gov, NCT03705611. Between Sept 8, 2018, and May 2, 2019, nine clusters were assigned to each trial arm, resulting in 4544 eligible women in the ANC cohort (1447 [31·8%] in the standard care group, 1465 [32·2%] in the HIVST only group, and 1632 [35·9%] in HIVST plus financial incentive group) and 708 eligible patients in the index cohort (234 [33·1%] in the standard care group, 169 [23·9%] in the HIVST only group, and 305 [42·9%] in the HIVST plus financial incentive group). 4461 (98·2%) of 4544 eligible women in the ANC cohort and 645 (91·1%) of 708 eligible patients in the index cohort were recruited, of whom 3378 (75·7%) in the ANC cohort and 439 (68·1%) in the index cohort were interviewed after 28 days. In the ANC cohort, the mean proportion of reported partner testing per cluster was 35·0% (SD 10·0) in the standard care group, 73·0% in HIVST only group (13·1, adjusted risk ratio [RR] 1·71, 95% CI 1·48-1·98; p<0·0001), and 65·2% in the HIVST plus financial incentive group (11·6, adjusted RR 1·62, 1·45-1·81; p<0·0001). In the index cohort, the geometric mean number of new HIV-positive sexual partners per cluster was 1·35 (SD 1·62) for the standard care group, 1·91 (1·78) for the HIVST only group (incidence rate ratio adjusted for number eligible as an offset in the negative binomial model 1·65, 95% CI 0·49-5·55; p=0·3370), and 3·20 (3·81) for the HIVST plus financial incentive group (3·11, 0·99-9·77; p=0·0440). Four self-resolving, temporary marital separations occurred due to disagreement in couples regarding HIV self-test kits. Although administration of HIVST kits in the ANC cohort, even when offered alongside a financial incentive, did not identify significantly more male patients with HIV than did standard care, out-of-clinic options for HIV testing appear more acceptable to many male partners of women with HIV, increasing test uptake. Viewed in the current context, this approach might allow continuation of services despite COVID-19-related lockdowns. Unitaid, through the Self-Testing Africa Initiative.

Sections du résumé

BACKGROUND
Secondary distribution of HIV self-testing (HIVST) kits by patients attending clinic services to their partners could improve the rate of HIV diagnosis. We aimed to investigate whether secondary administration of HIVST kits, with or without an additional financial incentive, via women receiving antenatal care (ANC) or via people newly diagnosed with HIV (ie, index patients) could improve the proportion of male partners tested or the number of people newly diagnosed with HIV.
METHODS
We did a three-arm, open-label, pragmatic, cluster-randomised trial of 27 health centres (clusters), eligible if they were a government primary health centre providing ANC, HIV testing, and ART services, across four districts of Malawi. We recruited women (aged ≥18 years) attending their first ANC visit and whose male partner was available, not already taking ART, and not already tested for HIV during this pregnancy (ANC cohort), and people (aged ≥18 years) with newly diagnosed HIV during routine clinic HIV testing who had at least one sexual contact not already known to be HIV-positive (index cohort). Centres were randomly assigned (1:1:1), using a public selection of computer-generated random allocations, to enhanced standard of care (including an invitation for partners to attend HIV testing services), HIVST only, or HIVST plus a US$10 financial incentive for retesting. The primary outcome for the ANC cohort was the proportion of male partners reportedly tested, as ascertained by interview with women in this cohort at day 28. The primary outcome for the index cohort was the geometric mean number of new HIV-positive people identified per facility within 28 days of enrolment, as measured by observed HIV test results. Cluster-level summaries compared intervention with standard of care by intention to treat. This trial is registered with ClinicalTrials.gov, NCT03705611.
FINDINGS
Between Sept 8, 2018, and May 2, 2019, nine clusters were assigned to each trial arm, resulting in 4544 eligible women in the ANC cohort (1447 [31·8%] in the standard care group, 1465 [32·2%] in the HIVST only group, and 1632 [35·9%] in HIVST plus financial incentive group) and 708 eligible patients in the index cohort (234 [33·1%] in the standard care group, 169 [23·9%] in the HIVST only group, and 305 [42·9%] in the HIVST plus financial incentive group). 4461 (98·2%) of 4544 eligible women in the ANC cohort and 645 (91·1%) of 708 eligible patients in the index cohort were recruited, of whom 3378 (75·7%) in the ANC cohort and 439 (68·1%) in the index cohort were interviewed after 28 days. In the ANC cohort, the mean proportion of reported partner testing per cluster was 35·0% (SD 10·0) in the standard care group, 73·0% in HIVST only group (13·1, adjusted risk ratio [RR] 1·71, 95% CI 1·48-1·98; p<0·0001), and 65·2% in the HIVST plus financial incentive group (11·6, adjusted RR 1·62, 1·45-1·81; p<0·0001). In the index cohort, the geometric mean number of new HIV-positive sexual partners per cluster was 1·35 (SD 1·62) for the standard care group, 1·91 (1·78) for the HIVST only group (incidence rate ratio adjusted for number eligible as an offset in the negative binomial model 1·65, 95% CI 0·49-5·55; p=0·3370), and 3·20 (3·81) for the HIVST plus financial incentive group (3·11, 0·99-9·77; p=0·0440). Four self-resolving, temporary marital separations occurred due to disagreement in couples regarding HIV self-test kits.
INTERPRETATION
Although administration of HIVST kits in the ANC cohort, even when offered alongside a financial incentive, did not identify significantly more male patients with HIV than did standard care, out-of-clinic options for HIV testing appear more acceptable to many male partners of women with HIV, increasing test uptake. Viewed in the current context, this approach might allow continuation of services despite COVID-19-related lockdowns.
FUNDING
Unitaid, through the Self-Testing Africa Initiative.

Identifiants

pubmed: 34143996
pii: S2214-109X(21)00175-3
doi: 10.1016/S2214-109X(21)00175-3
pmc: PMC8220130
pii:
doi:

Substances chimiques

Reagent Kits, Diagnostic 0

Banques de données

ClinicalTrials.gov
['NCT03705611']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e977-e988

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Wellcome Trust
ID : 200901/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

World Health Organization; licensee Elsevier. This is an Open Access article published under the CC BY 3.0 IGO license.

Déclaration de conflit d'intérêts

Declaration of interests ELC reports grants from the London School of Hygiene & Tropical Medicine, during the conduct of the study. CCJ reports grants from Unitaid, during the conduct of the study; and grants from Bill & Melinda Gates Foundation and the US Agency for International Development, outside of the submitted work. All other authors declare no competing interests.

Références

J Med Ethics. 2015 Oct;41(10):809-13
pubmed: 26276789
N Engl J Med. 2019 Jul 18;381(3):207-218
pubmed: 31314965
Perspect Clin Res. 2011 Jul;2(3):109-12
pubmed: 21897887
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Lancet Glob Health. 2020 Feb;8(2):e276-e287
pubmed: 31981557
Clin Infect Dis. 2014 Aug 15;59(4):589-95
pubmed: 24803381
PLoS Med. 2014 Feb 25;11(2):e1001608
pubmed: 24586123
Clin Infect Dis. 2020 Jun 26;:
pubmed: 32588883
PLoS One. 2018 Nov 14;13(11):e0207263
pubmed: 30427889
J Int AIDS Soc. 2019 Jul;22 Suppl 3:e25292
pubmed: 31321917
PLoS One. 2020 Jan 15;15(1):e0227623
pubmed: 31940422
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25253
pubmed: 30907496
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25251
pubmed: 30907508
BMC Public Health. 2021 Jan 6;21(1):60
pubmed: 33407298
MMWR Morb Mortal Wkly Rep. 2019 May 31;68(21):474-477
pubmed: 31145718
Lancet. 2007 Feb 24;369(9562):657-66
pubmed: 17321311
AIDS Behav. 2020 Jun;24(6):1929-1941
pubmed: 31853772
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003362
pubmed: 19370585
PLoS Med. 2015 Sep 08;12(9):e1001873
pubmed: 26348035
JAMA Intern Med. 2020 Jan 1;180(1):117-125
pubmed: 31738378
PLoS Med. 2016 Nov 8;13(11):e1002166
pubmed: 27824882
Lancet. 2007 Feb 24;369(9562):643-56
pubmed: 17321310
Lancet HIV. 2016 Jun;3(6):e266-74
pubmed: 27240789
Bull World Health Organ. 2018 Jan 1;96(1):69-71
pubmed: 29403103
PLoS Med. 2019 Jan 2;16(1):e1002719
pubmed: 30601823
JAMA. 2014 Aug 20;312(7):703-11
pubmed: 25042290
J Int AIDS Soc. 2017 Jun 26;20(1):21610
pubmed: 28691442

Auteurs

Augustine T Choko (AT)

TB-HIV Group, Malawi-Liverpool-Wellcome Clinical Research Programme, Chichiri, Blantyre, Malawi. Electronic address: augutc@gmail.com.

Katherine Fielding (K)

Department of Infectious Disease Epidemiology and MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.

Cheryl C Johnson (CC)

Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK; Global HIV, Hepatitis and STI Programme, WHO, Geneva, Switzerland.

Moses K Kumwenda (MK)

TB-HIV Group, Malawi-Liverpool-Wellcome Clinical Research Programme, Chichiri, Blantyre, Malawi.

Richard Chilongosi (R)

Population Services International, Lilongwe, Malawi.

Rachel C Baggaley (RC)

Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK.

Rose Nyirenda (R)

Department of HIV-AIDS, Ministry of Health, Lilongwe, Malawi.

Linda A Sande (LA)

TB-HIV Group, Malawi-Liverpool-Wellcome Clinical Research Programme, Chichiri, Blantyre, Malawi; Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK.

Nicola Desmond (N)

TB-HIV Group, Malawi-Liverpool-Wellcome Clinical Research Programme, Chichiri, Blantyre, Malawi; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.

Karin Hatzold (K)

Population Services International, Johannesburg, South Africa.

Melissa Neuman (M)

Department of Infectious Disease Epidemiology and MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.

Elizabeth L Corbett (EL)

TB-HIV Group, Malawi-Liverpool-Wellcome Clinical Research Programme, Chichiri, Blantyre, Malawi; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH